Designing circulating tumor DNA-based interventional clinical trials in oncology

Genome Med. 2019 Apr 19;11(1):22. doi: 10.1186/s13073-019-0634-x.


Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting patients for tailored treatments, and in revealing mechanisms of response or resistance. Here, we discuss the incorporation of ctDNA into clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Circulating Tumor DNA / blood*
  • Clinical Trials as Topic*
  • Humans
  • Neoplasms / blood*
  • Neoplasms / pathology
  • Neoplasms / therapy


  • Biomarkers, Tumor
  • Circulating Tumor DNA